Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases
Immuno-chemotherapy is a first-line optional treatment strategy in addition to targeted therapy for NSCLC patients with primary METamp. Foxp3-negative expression better predicts the near-term efficacy of immunotherapy.
Authors
- Yanjun Xu (ORCID: https://orcid.org/0000-0001-7187-8804)
- Xuanhong Jin (ORCID: https://orcid.org/0009-0002-9348-1837)
- Kaibo Ding
- Dujiang Liu
Institutions
- Sir Run Run Shaw Hospital (CN)
- Zhejiang Cancer Hospital (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2024-10-19
- DOI
- https://doi.org/10.1016/j.intimp.2024.113391
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Zhejiang Province